연구성과로 돌아가기

2024 연구자 정보 (687 / 1079)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lee, Min Ki
(Lee, MK) ⓘ 		Pusan Natl Univ Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Pusan 49241, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ hyeonhwa1@gmail.com;jclee@amc.seoul.kr;droij@chonnam.ac.kr;dognose79@naver.com;leemk@pusan.ac.kr;ckpaul@catholic.ac.kr;kyleemd@kuh.ac.kr;cmcksj@catholic.ac.kr;ccm@amc.seoul.kr; ⓘ
Lee, Sung Yong
(Lee, SY) ⓘ 		Korea Univ, Guro Hosp, Coll Med, Div Pulm Allergy & Crit Care Med,Dept Internal Med, Seoul 08308, South Korea
Korea Univ, Guro Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med,Coll Med, Seoul, South Korea
Korea Univ, Guro Hosp, Coll Med, Div Pulm,Dept Internal Med, Seoul, South Korea ⓘ 		ADE-2110-2022
Lee, Joo Yong ⓘ 		0000-0002-8693-5792
LEE, SUNG YONG ⓘ 		[JCR상위 25.9] Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
[JCR상위 30.8] The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study
[JCR상위 46.8] Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea ⓘ 		SCIE ⓘ 25.9 ONCOLOGY
ONCOLOGY;RESPIRATORY SYSTEM ⓘ 		hyeonhwa1@gmail.com;jclee@amc.seoul.kr;droij@chonnam.ac.kr;dognose79@naver.com;leemk@pusan.ac.kr;ckpaul@catholic.ac.kr;kyleemd@kuh.ac.kr;cmcksj@catholic.ac.kr;ccm@amc.seoul.kr;
ccm@amc.seoul.kr;
drhrkim10@gmail.com;simi20083132@gmail.com; ⓘ
Lim, Jun Hyeok
(Lim, JH) ⓘ 		Inha Univ Hosp, Dept Internal Med, Incheon 22332, South Korea ⓘ ABA-5277-2021
Lim, Jun Hyeok ⓘ
ⓘ 		[JCR상위 25.9] Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ hyeonhwa1@gmail.com;jclee@amc.seoul.kr;droij@chonnam.ac.kr;dognose79@naver.com;leemk@pusan.ac.kr;ckpaul@catholic.ac.kr;kyleemd@kuh.ac.kr;cmcksj@catholic.ac.kr;ccm@amc.seoul.kr; ⓘ
Oh, In-Jae
(Oh, IJ) ⓘ 		Chonnam Natl Univ, Med Sch, Dept Internal Med, Jeollanamdo 58128, South Korea
Hwasun Hosp, Gwangju 58128, South Korea
Chonnam Natl Univ, Hwasun Hosp, Med Sch, Dept Internal Med, Hwasun, South Korea ⓘ 		AAG-5919-2020
Oh, In-Jae ⓘ 		0000-0003-4837-1321
Oh, In-Jae ⓘ 		[JCR상위 25.9] Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
[JCR상위 30.8] The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study ⓘ 		SCIE ⓘ 25.9 ONCOLOGY ⓘ hyeonhwa1@gmail.com;jclee@amc.seoul.kr;droij@chonnam.ac.kr;dognose79@naver.com;leemk@pusan.ac.kr;ckpaul@catholic.ac.kr;kyleemd@kuh.ac.kr;cmcksj@catholic.ac.kr;ccm@amc.seoul.kr;
ccm@amc.seoul.kr; ⓘ
Park, Chan Kwon
(Park, CK) ⓘ 		Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Allergy & Crit Care Med, Seoul 16247, South Korea
Catholic Univ, Korean Yeouido St Marys Hosp, Dept Pulm & Crit Care Med, Seoul, South Korea ⓘ
ⓘ 		0000-0002-4107-444X
Park, Chan Kwon ⓘ 		[JCR상위 25.9] Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
[JCR상위 46.8] Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea ⓘ 		SCIE ⓘ 25.9 ONCOLOGY
ONCOLOGY;RESPIRATORY SYSTEM ⓘ 		hyeonhwa1@gmail.com;jclee@amc.seoul.kr;droij@chonnam.ac.kr;dognose79@naver.com;leemk@pusan.ac.kr;ckpaul@catholic.ac.kr;kyleemd@kuh.ac.kr;cmcksj@catholic.ac.kr;ccm@amc.seoul.kr;
drhrkim10@gmail.com;simi20083132@gmail.com; ⓘ
Park, Jin Kyung
(Park, JK) ⓘ 		Ildong Pharmaceut Co, 2,Baumoe Ro 27 gil, Seoul 06752, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr; ⓘ
Park, Junhee
(Park, J) ⓘ 		제1저자 Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu 41944, South Korea ⓘ
ⓘ 		0009-0000-4540-8745
Park, Junhee ⓘ 		[JCR상위 25.9] Localized Radiotherapy for Classic Kaposi's Sarcoma: An Analysis of Lesion Characteristics and Treatment Response ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ jhp1247@knuh.kr;jelee@knu.ac.kr; ⓘ
Park, Young Joo
(Park, YJ) ⓘ 		Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Coll Med, Busan 49241, South Korea
Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea
Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Internal Med, Pusan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
[JCR상위 1.7] Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis
[JCR상위 59.0] Impact of diabetes mellitus and hypertension on renal function during first-line targeted therapy for metastatic renal cell carcinoma: a retrospective multicenter study ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY
ANDROLOGY;UROLOGY & NEPHROLOGY ⓘ 		mongmani@daum.net;who54@hanmail.net;jheo@pusan.ac.kr;phorni@naver.com;juya0630@naver.com;yikiyoun@hanmail.net;deblue00@naver.com;psyoung0419@gmail.com;chung50@dsmc.or.kr;jangha106@dsmc.or.kr;wytak@knu.ac.kr;
jheo@pusan.ac.kr;
leechanho@naver.com; ⓘ
Seo, Donghyun
(Seo, D) ⓘ 		제1저자 Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Vessel Organ Interact Res Ctr, Daegu 41566, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Dihydrotestosterone Enhances MICA-Mediated Immune Responses to Epstein-Barr Virus-Associated Gastric Carcinoma ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ puppu04050@naver.com;qkek0810@naver.com;cmy1004g@knu.ac.kr;ihappy278@knu.ac.kr;yshggid@gmail.com;2009045032@knu.ac.kr;inukjung@knu.ac.kr;hyosun1102@duksung.ac.kr;hkang72@knu.ac.kr; ⓘ
Sohn, Joo Hyun
(Sohn, JH) ⓘ 		Hanyang Univ, Guri Hosp, Dept Internal Med, 153 Gyeongchun Ro, Guri 11923, South Korea ⓘ
ⓘ 		0000-0002-8977-4509
Sohn, Joo Hyun ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr; ⓘ
Um, Soon Ho
(Um, SH) ⓘ 		교신저자 Korea Univ, Anam Hosp, Coll Med, Dept Internal Med, 73 Goryeodae Ro, Seoul 02841, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr; ⓘ
Woo, Hyun Young
(Woo, HY) ⓘ 		Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Coll Med, Busan 49241, South Korea
Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea
Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
Pusan Natl Univ, Pusan Natl Univ Hosp, Coll Med, Pusan, South Korea
Pusan Natl Univ, Pusan, South Korea
Pusan Natl Univ Hosp, Med Res Inst, Pusan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
[JCR상위 1.7] Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis
[JCR상위 4.4] BENEFICIAL EFFECT OF COMBINED RADIATION THERAPY IN ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT OF HEPATOCELLULAR CARCINOMA PATIENTS WITH MAIN PORTAL VEIN TUMOR THROMBOSIS OR BILE DUCT INVASION
[JCR상위 4.4] VALIDATION OF AN ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTION OF HEPATOCELLULAR CARCINOMA RISK AFTER ORAL ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY ⓘ 		mongmani@daum.net;who54@hanmail.net;jheo@pusan.ac.kr;phorni@naver.com;juya0630@naver.com;yikiyoun@hanmail.net;deblue00@naver.com;psyoung0419@gmail.com;chung50@dsmc.or.kr;jangha106@dsmc.or.kr;wytak@knu.ac.kr;
jheo@pusan.ac.kr; ⓘ
Yang, Jin Mo
(Yang, JM) ⓘ 		Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Internal Med, 93 Jungbu Daero, Suwon 16247, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr; ⓘ
Yi, Ki Youn
(Yi, KY) ⓘ 		Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Coll Med, Busan 49241, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ mongmani@daum.net;who54@hanmail.net;jheo@pusan.ac.kr;phorni@naver.com;juya0630@naver.com;yikiyoun@hanmail.net;deblue00@naver.com;psyoung0419@gmail.com;chung50@dsmc.or.kr;jangha106@dsmc.or.kr;wytak@knu.ac.kr; ⓘ
Yim, Hyung Joon
(Yim, HJ) ⓘ 		제1저자 교신저자 Korea Univ, Dept Internal Med, Ansan Hosp, 123 Jeokgeum Ro, Ansan 15355, South Korea
Korea Univ, Ansan Hosp, Coll Med, Ansan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy
[JCR상위 3.2] Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: a nationwide, multicentre, retrospective cohort study ⓘ 		SCIE ⓘ 3.2 ONCOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr;
drwon1@snu.ac.kr;hanseungbong@gmail.com;ksukorea@yuhs.ac; ⓘ
페이지 이동: